Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;18(3):1093-102.
doi: 10.1016/j.bmc.2009.12.057. Epub 2009 Dec 29.

Utilization of the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide scaffold in the design of potential inhibitors of human neutrophil proteinase 3

Affiliations

Utilization of the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide scaffold in the design of potential inhibitors of human neutrophil proteinase 3

Dengfeng Dou et al. Bioorg Med Chem. 2010 Feb.

Abstract

The S' subsites of human neutrophil proteinase 3 (Pr 3) were probed by constructing diverse libraries of compounds based on the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide using combinational and click chemistry methods. The multiple points of diversity embodied in the heterocyclic scaffold render it well-suited to the exploration of the S' subsites of Pr 3. Molecular modeling studies suggest that further exploration of the S' subsites of Pr 3 using the aforementioned heterocyclic scaffold may lead to the identification of highly selective, reversible competitive inhibitors of Pr 3.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mercury drawing of compound 13a, showing the 50% thermal ellipsoids. Hydrogen atoms have been omitted for clarity.
Figure 2
Figure 2
Inhibitor (II) design rationale.
Figure 3
Figure 3
Compound 13g bound to Pr3. The structure was generated from molecular simulation. Ligand rendered as CPK-colored sticks. Receptor surface colors correspond to: yellow = nonpolar, white = polar alkyls, blue = polar N, cyan = polar H, red = O.
Figure 4
Figure 4
Inhibitory activity of selected compounds against human neutrophil elastase and proteinase 3.
Figure 5
Figure 5
Mechanism of transition state inhibitor.
Scheme 1
Scheme 1
Scheme 2
Scheme 2
Scheme 3
Scheme 3
Scheme 4
Scheme 4

Similar articles

Cited by

References

    1. Churg A, Wright JL. Curr. Opin. Pulm. Med. 2005;11:153–159. - PubMed
    1. Barnes PJ. Pharmacol. Rev. 2004;56:515–548. - PubMed
    1. Barnes PJ, Stockley RA. Eur. Respir. J. 2005;25 1984-1106. - PubMed
    1. Shapiro SD, Ingenito EP. Am. J. Respir. Cell Mol. Biol. 2005;32:367–372. - PubMed
    1. Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, Belaaouaj A. Am. J. Pathol. 2003;163:2329–2335. - PMC - PubMed

Publication types

MeSH terms